Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
CD20 expression
Description:
The presence or level of the CD20 cell-surface protein, commonly assessed in B-cell malignancies and other lymphoid disorders.
Primary topic:
Lymphoma Diagnosis and Treatment (37%)
Related topics:
Lymphoma Diagnosis and Treatment (37%),
Acute Lymphoblastic Leukemia research (18%),
Chronic Lymphocytic Leukemia Research (16%)
OpenAlex ID:
keywords/cd20-expression
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
2003
·
Mitchell R Smith
·
Oncogene
·
952
Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia
2010
·
Deborah A. Thomas
, Susan O'Brien
, et al.
·
Journal of Clinical Oncology
·
444
The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein–kinase–dependent mechanism
2002
·
Irene Munk Pedersen
, Anne Mette Buhl
, et al.
·
Blood
·
243
Cd20 (pan‐B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes
1993
·
Lance E. Hultin
, Mary Ann Hausner
, et al.
·
Cytometry
·
218
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
2008
·
Deborah A. Thomas
, Susan O'Brien
, et al.
·
Blood
·
213
PDF
Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
2011
·
Luca Bologna
, Elisa Gotti
, et al.
·
The Journal of Immunology
·
207
PDF
Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin
2001
·
Maria-Ana Ghetie
, Helen Bright
, et al.
·
Blood
·
199
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
2008
·
Nathalie A. Johnson
, Merrill Boyle
, et al.
·
Blood
·
180
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
2003
·
Anas Younes
, Jorge Romaguera
, et al.
·
Cancer
·
176
PDF
Prognostic Factors in Chemotherapy-Treated Patients with HIV-Associated Plasmablastic Lymphoma
2010
·
Jorge J. Castillo
, Eric S. Winer
, et al.
·
The Oncologist
·
148
A prospective study of mediastinal gray-zone lymphoma
2014
·
Wyndham H. Wilson
, Stefania Pittaluga
, et al.
·
Blood
·
137
CD20+ T-cell Lymphoma: Clinicopathologic Analysis of 9 Cases and a Review of the Literature
2008
·
Aliyah Rahemtullah
, Janina A. Longtine
, et al.
·
The American Journal of Surgical Pathology
·
126
Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
2009
·
S. Maury
, F. Huguet
, et al.
·
Haematologica
·
118
PDF
HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
2010
·
R Shimizu
, J Kikuchi
, et al.
·
Leukemia
·
113
Anti‐CD20 monoclonal antibody therapy in multiple myeloma
2008
·
Prashant Kapoor
, Patricia T. Greipp
, et al.
·
British Journal of Haematology
·
112
PDF
Infusion-related reactions to rituximab: frequency, mechanisms and predictors
2018
·
Franciane Paul
, Guillaume Cartron
·
Expert Review of Clinical Immunology
·
107
Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia
2006
·
Sima Jeha
, Frederick Behm
, et al.
·
Blood
·
105
PDF
The predictive significance of CD20 expression in B-cell lymphomas
2011
·
Veronika Kloboves Prevodnik
, Jaka Lavrenčak
, et al.
·
Diagnostic Pathology
·
100
PDF
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation
2015
·
F Pozzo
, T Bittolo
, et al.
·
Leukemia
·
99
PDF
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
2023
·
Stephen J. Schuster
, Ling-Yuh Huw
, et al.
·
Blood
·
93
Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era
2004
·
Irene Ghobrial
, Thomas Habermann
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
92
Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies
2011
·
Guillaume Cartron
, Ralf Ulrich Trappe
, et al.
·
Clinical Cancer Research
·
90
Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial
2022
·
Xiaotao Huang
, Qiaodan Liu
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
87
PDF
Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in‐situ hybridization in 510 patients
2008
·
Constantine S. Tam
, Joselle Otero‐Palacios
, et al.
·
British Journal of Haematology
·
86
Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
2017
·
Yvonne W. S. Jauw
, Josée M. Zijlstra
, et al.
·
PLoS ONE
·
84
PDF
Show more works
View as search
Works count:
419
Citation count:
8,467
Year
Topic
Type